Main Library
One of the most consequential shifts I’ve seen during 20 years in the biopharmaceutical industry is happening right now: A combined focus on patient-centricity and health equity is changing how companies approach end-to-end drug development and how we reach patients who’ve historically been left behind.
As the child of immigrant parents, who has lived in many countries and experienced different cultures, I have come to understand and witness first-hand some of the challenges that minority communities face in receiving quality healthcare because of a myriad of barriers including language, access to information and cultural differences. As a practicing physician for 10 years in the UK’s National Health Service, I’ve also witnessed how the social determinants of health can dramatically impact patient outcomes, simply due to circumstances beyond an individual’s control.
As chief medical officer for Jazz Pharmaceuticals, I’m proud to have our commitment focused on two key areas – patient-centricity and heath equity – as we commit considerable time and resources as we aspire to improve health literacy and incorporate the patient voice into every aspect of our R&D across oncology and neuroscience.